Currently out of the existing stock ratings of Christopher Raymond, 389 are a BUY (78.74%), 100 are a HOLD (20.24%), 5 are a SELL (1.01%).

Christopher Raymond

Work Performance Price Targets & Ratings Chart

Analyst Christopher Raymond, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 49.29% that have a potential upside of 40.98% achieved within 248 days.

Christopher Raymond’s has documented 975 price targets and ratings displayed on 41 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ACRS, Aclaris Therapeutics at 09-Jul-2025.

Wall Street Analyst Christopher Raymond

Analyst best performing recommendations are on ALXO (ALX ONCOLOGY HOLDINGS ).
The best stock recommendation documented was for DCPH (DECIPHERA PHARMACEUTICALS LLC) at 5/31/2018. The price target of $35 was fulfilled within 4 days with a profit of $9.28 (36.08%) receiving and performance score of 90.2.

Average potential price target upside

of $90.16 (21.46%) on REGN (REGENERON PHARMACEUTICALS).
of $78.35 (68.57%) on ALVR (ALLOVIR ).
of $53.69 (46.76%) on ALXN (ALEXION PHARMACEUTICALS).

ABBV AbbVie ACRS Aclaris Therapeutics AIMT Aimmune Therapeutics AKBA Akebia Ther ALVR Allovir ALXN Alexion Pharmaceuticals AMAG AMAG Pharmaceuticals AMGN Amgen ARDX Ardelyx BIIB Biogen BMRN Biomarin Pharmaceutical COGT Cogent Biosciences DCPH Deciphera Pharmaceuticals LLC GRAY Graybug Vision INO Inovio Pharmaceuticals ONCR Oncorus RARE Ultragenyx REGN Regeneron Pharmaceuticals APTX Aptinyx BPMC Blueprint Medicines Corp CELG Celgene INZY Inozyme Pharma MGTX MeiraGTx Holdings PLC OTIC Otonomy RIGL Rigel Pharmaceuticals BOLD Audentes Therapeutics CBIO Catalyst Biosciences KNTE Kinnate Biopharma PRVL Prevail Therapeutics SLDB Solid Biosciences LLC XLRN Acceleron Pharma BCRX BioCryst Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd NUVL Nuvalent ALXO Alx Oncology Holdings KPTI Karyopharm Therapeutics RMTI Rockwell Medical SPHS Sophiris Bio VECT VectivBio Holding AG VRTX Vertex Pharmaceuticals QTTB Q32 Bio

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Geoff Meacham (CITI)